Drug Profile
Research programme: Gram-positive infection therapeutics - ContraFect
Alternative Names: CF 302; CF 303; CF 304; CF 305; CF 306; CF-307; CF-308; CF-309; Direct lytic agents - ContraFect; Gram-positive lysins - ContrafectLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Rockefeller University
- Developer ContraFect
- Class Antibacterials; Endolysins; Enzymes; Recombinant proteins
- Mechanism of Action Cell membrane inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax; Enterococcal infections; Pneumococcal infections; Streptococcal infections
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Anthrax in USA
- 28 May 2021 No recent reports of development identified for research development in Enterococcal-infections in USA
- 28 May 2021 No recent reports of development identified for research development in Pneumococcal-infections in USA